PHAT · Insider trading · 13F holders · Congress trades
Phathom Pharmaceuticals, Inc. (PHAT)
Who is buying and selling PHAT: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 15
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $0
- Congress trades, 12 months
- 0
PHAT at a glance
- No open-market insider purchases or sales of PHAT were filed in the last 90 days.
- 15 13F filers hold PHAT among their 50 largest positions, worth $247.2M combined, including Oleg Nodelman. The biggest bets by portfolio weight are Propel Bio Management, LLC (6.0%), Frazier Life Sciences Management, L.P. (2.9%) and 683 Capital Management, LLC (1.9%). In their latest 13Fs, 1 manager opened a new position and 2 added to one.
- No member of Congress has disclosed a trade in PHAT.
PHAT insider trading
No open-market insider purchases or sales of PHAT were filed in the last 90 days.
Who owns PHAT? Hedge funds and superinvestors
15 13F filers hold PHAT among their 50 largest positions, worth $247.2M combined, including Oleg Nodelman. The biggest bets by portfolio weight are Propel Bio Management, LLC (6.0%), Frazier Life Sciences Management, L.P. (2.9%) and 683 Capital Management, LLC (1.9%). In their latest 13Fs, 1 manager opened a new position and 2 added to one.
Superinvestors holding PHAT: Oleg Nodelman 0.3%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P.Hedge fund | 2.9% | $135.3M | 12,466,489 | +0.0% shares | Q2 2026 |
| Carlyle Group Inc.Hedge fund | 0.4% | $37.9M | 3,496,808 | +0.0% shares | Q2 2026 |
| NEA Management Company, LLCHedge fund | 1.3% | $21.3M | 1,960,169 | +0.0% shares | Q2 2026 |
| 683 Capital Management, LLCHedge fund | 1.9% | $20.1M | 1,850,000 | +0.0% shares | Q2 2026 |
| Propel Bio Management, LLCHedge fund | 6.0% | $11.4M | 1,050,358 | +24.9% shares | Q2 2026 |
| Oleg NodelmanHedge fund | 0.3% | $6.8M | 625,000 | +0.0% shares | Q2 2026 |
| StepStone Group LPHedge fund | 0.2% | $4.6M | 422,085 | +0.0% shares | Q2 2026 |
| Avidity Partners Management LPHedge fund | 0.3% | $2.2M | 200,000 | -19.8% shares | Q2 2026 |
| Opaleye Management Inc.Hedge fund | 0.2% | $2.0M | 185,589 | — | Q2 2026 |
| Jones Hill Capital LPHedge fund | 0.4% | $1.8M | 161,486 | New | Q2 2026 |
| Diadema Partners LPHedge fund | 0.5% | $1.4M | 129,950 | — | Q2 2026 |
| Stonepine Capital Management, LLCHedge fund | 0.7% | $922K | 85,010 | +70.0% shares | Q2 2026 |
| Birchview Capital, LPWealth manager | 0.3% | $597K | 55,000 | -71.8% shares | Q2 2026 |
| Pale Fire Capital SEAsset manager | 0.0% | $539K | 49,713 | — | Q2 2026 |
| Penn Mutual Asset ManagementInstitutional asset manager | 2.0% | $458K | 62,802 | +0.0% shares | Q3 2026 |
Each manager counts with its latest 13F (Q3 2026: 1, Q2 2026: 14). Screen PHAT in the grand portfolio →
PHAT stock trades by members of Congress
No member of Congress has disclosed a trade in PHAT.
PHAT questions and answers
Are insiders buying PHAT stock?
No open-market insider purchases or sales of PHAT were filed in the last 90 days.
Which hedge funds own PHAT?
15 13F filers hold PHAT among their 50 largest positions, worth $247.2M combined, including Oleg Nodelman. The biggest bets by portfolio weight are Propel Bio Management, LLC (6.0%), Frazier Life Sciences Management, L.P. (2.9%) and 683 Capital Management, LLC (1.9%). In their latest 13Fs, 1 manager opened a new position and 2 added to one.
Has Congress traded PHAT?
No member of Congress has disclosed a trade in PHAT.
Who is the largest holder of PHAT?
Among 13F filers, Frazier Life Sciences Management, L.P. reports the largest PHAT position, $135.3M (12,466,489 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Propel Bio Management, LLC's: 6.0% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.